FDA Approves Oral Wegovy: Game Changer for Dieters?

The Food and Drug Administration has granted approval for an oral version of Wegovy, Novo Nordisk's widely recognized weight loss medication. This marks the introduction of the first pill form for a GLP-1 drug specifically for weight management, with a similar option from Eli Lilly anticipated soon. These GLP-1 compounds, initially for diabetes, have surged in popularity due to their effectiveness in facilitating significant weight loss.

Dr. Christopher McGowan highlighted the pill's potential to broaden treatment options, noting that pills are often more psychologically acceptable and easier to integrate into daily routines than injections. While the exact list price is unreleased, it's expected to be lower than injectable versions. Clinical trials indicate that the highest dose of the Wegovy pill led to an average weight loss of 16.6% over 64 weeks, comparable to its injectable form.

However, maintaining strict adherence to the daily regimen—taking the pill first thing in the morning on an empty stomach with water—is critical, as deviations resulted in less weight loss in trials. Gastrointestinal side effects, such as nausea and vomiting, are common, potentially intensified by the pill's immediate release. Experts are still evaluating its 'real-world performance' regarding patient compliance and long-term efficacy.